Profile data is unavailable for this security.
About the company
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
- Revenue in USD (TTM)168.34m
- Net income in USD-126.09m
- Incorporated2004
- Employees280.00
- LocationXencor Inc465 N. HALSTEAD ST., SUITE 200PASADENA 91107United StatesUSA
- Phone+1 (626) 305-5900
- Fax+1 (626) 305-0350
- Websitehttps://xencor.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tarsus Pharmaceuticals Inc | 17.45m | -135.89m | 1.30bn | 244.00 | -- | 6.00 | -- | 74.29 | -4.58 | -4.58 | 0.5939 | 5.76 | 0.0707 | -- | 1.64 | 71,504.10 | -55.09 | -31.56 | -61.63 | -33.82 | 90.87 | -- | -778.89 | -242.59 | 6.85 | -- | 0.1315 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
Collegium Pharmaceutical Inc | 566.77m | 48.16m | 1.31bn | 197.00 | 46.37 | 6.67 | 6.62 | 2.31 | 0.8823 | 0.8823 | 12.53 | 6.13 | 0.4891 | 6.10 | 3.13 | 2,876,990.00 | 4.16 | 2.79 | 6.75 | 4.80 | 57.55 | 50.88 | 8.50 | 5.16 | 1.10 | 2.59 | 0.7734 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
AbCellera Biologics Inc | 38.03m | -146.40m | 1.31bn | 586.00 | -- | 1.13 | -- | 34.57 | -0.5062 | -0.5062 | 0.1315 | 3.96 | 0.0251 | -- | 1.10 | 64,890.79 | -9.67 | 6.08 | -10.49 | 6.67 | -- | -- | -384.99 | 24.69 | 7.32 | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
Gyre Therapeutics Inc | 0.00 | -44.24m | 1.34bn | 7.00 | -- | -- | -- | -- | -20.60 | -20.60 | 0.00 | 1.39 | 0.00 | -- | -- | 0.00 | -215.90 | -58.25 | -235.61 | -72.12 | -- | -- | -- | -817.06 | -- | -- | 0.00 | -- | -89.18 | -4.85 | 90.63 | -- | -- | -- |
Ironwood Pharmaceuticals, Inc. | 442.74m | -1.00bn | 1.35bn | 267.00 | -- | -- | -- | 3.05 | -6.51 | -6.51 | 2.59 | -2.21 | 0.5634 | -- | 3.62 | 1,658,184.00 | -131.28 | -4.54 | -162.45 | -5.20 | -- | -- | -233.00 | -7.81 | -- | 63.79 | 1.98 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
Pacira Biosciences Inc | 674.98m | 41.96m | 1.35bn | 711.00 | 42.78 | 1.55 | 11.48 | 2.00 | 0.6789 | 0.6789 | 12.33 | 18.72 | 0.4147 | 1.84 | 6.62 | 949,336.10 | 2.58 | 3.35 | 2.79 | 3.98 | 72.64 | 72.63 | 6.22 | 8.57 | 4.17 | 9.85 | 0.3752 | 0.00 | 1.22 | 14.88 | 163.72 | -- | 0.8761 | -- |
Prothena Corporation PLC | 91.37m | -147.03m | 1.35bn | 173.00 | -- | 2.41 | -- | 14.79 | -2.80 | -2.80 | 1.68 | 10.46 | 0.1256 | -- | -- | 528,150.30 | -20.22 | -14.20 | -21.82 | -15.11 | -- | -- | -160.92 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
Spyre Therapeutics Inc | 886.00k | -338.79m | 1.35bn | 30.00 | -- | -- | -- | 1,528.43 | -75.04 | -75.04 | 0.1285 | 7.45 | 0.0043 | -- | 4.73 | 29,533.33 | -164.06 | -101.87 | -184.94 | -118.83 | -- | -- | -38,238.15 | -2,949.59 | -- | -- | 0.00 | -- | -61.96 | -25.61 | -304.21 | -- | -- | -- |
Immunome Inc | 10.19m | -21.96m | 1.36bn | 37.00 | -- | 51.25 | -- | 133.34 | -1.80 | -1.80 | 0.8369 | 0.4979 | 0.1648 | -- | -- | 275,459.50 | -35.50 | -- | -47.11 | -- | -- | -- | -215.44 | -- | -- | -- | 0.00 | -- | -- | -- | -51.83 | -- | -- | -- |
Vir Biotechnology Inc | 86.18m | -615.06m | 1.36bn | 587.00 | -- | 0.856 | -- | 15.83 | -4.59 | -4.59 | 0.6425 | 11.80 | 0.0365 | -- | -- | 146,814.30 | -26.06 | -0.6081 | -30.49 | -0.7192 | 96.79 | -- | -713.76 | -1.53 | -- | -- | 0.00 | -- | -94.67 | 51.87 | -219.24 | -- | 16.77 | -- |
Xencor Inc | 168.34m | -126.09m | 1.37bn | 280.00 | -- | 2.04 | -- | 8.14 | -2.10 | -2.10 | 2.79 | 10.96 | 0.1872 | -- | 8.36 | 601,207.10 | -14.04 | -3.70 | -15.30 | -4.12 | -- | -- | -75.00 | -15.92 | -- | -- | 0.0304 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
Day One Biopharmaceuticals Inc | 0.00 | -188.92m | 1.38bn | 155.00 | -- | 3.97 | -- | -- | -2.37 | -2.37 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -52.11 | -- | -55.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
Ocular Therapeutix Inc | 58.44m | -80.74m | 1.38bn | 267.00 | -- | 11.74 | -- | 23.68 | -0.9939 | -0.9939 | 0.7233 | 0.7927 | 0.2912 | 2.47 | 2.46 | 218,883.90 | -40.23 | -46.70 | -48.19 | -54.18 | 90.96 | 89.36 | -138.15 | -228.65 | 6.59 | -6.57 | 0.4512 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
Soleno Therapeutics Inc | 0.00 | -38.99m | 1.39bn | 33.00 | -- | 8.62 | -- | -- | -2.97 | -2.97 | 0.00 | 4.97 | 0.00 | -- | -- | 0.00 | -37.64 | -53.90 | -41.40 | -61.85 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -62.00 | -- | -- | -- |
Kiniksa Pharmaceuticals Ltd | 270.26m | 14.08m | 1.41bn | 297.00 | 124.98 | 3.21 | 85.94 | 5.22 | 0.1599 | 0.1599 | 3.74 | 6.23 | 0.5482 | 1.27 | 13.00 | 909,962.90 | 2.86 | -16.49 | 3.22 | -18.72 | 87.64 | -- | 5.21 | -53.64 | 3.85 | -- | 0.00 | -- | 22.74 | -- | -92.32 | -- | -52.35 | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Dec 2023 | 10.07m | 16.55% |
PRIMECAP Management Co.as of 31 Dec 2023 | 8.90m | 14.62% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 6.63m | 10.89% |
EcoR1 Capital, LLCas of 31 Dec 2023 | 5.28m | 8.68% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 3.36m | 5.52% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 3.33m | 5.47% |
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 2.56m | 4.21% |
Armistice Capital LLCas of 31 Dec 2023 | 1.50m | 2.46% |
T. Rowe Price Investment Management, Inc.as of 31 Dec 2023 | 1.35m | 2.22% |
Geode Capital Management LLCas of 31 Dec 2023 | 1.31m | 2.16% |